Hair loss concerns and treatments like Minoxidil and Finasteride are humorously discussed. The community's quirks and dedication to battling hair loss are highlighted.
A humorous discussion about a scalp massager used in a barber shop, with no mention of specific hair loss treatments like Minoxidil, finasteride, or RU58841. The massager is described as pleasurable but not a treatment for hair loss.
A user wants to dilute a melatonin sublingual spray to 0.0033% for use as a topical hair loss treatment. They ask if distilled water can be used for dilution and how much is needed for stability over months.
Efforts to find a Canadian dermatologist in the US to prescribe H&W's topical finasteride for hair loss. The user is willing to fund a crowd-share effort to identify prospects.
The user is considering switching from a stamp to a pen for hair treatment due to poor results with the stamp. They are concerned about the availability of pen refills and are seeking better outcomes with the pen.
The conversation is about the potential release of GT20029 on the grey market and concerns about its safety and authenticity. One user advises waiting for the official release by Kintor.
The conversation is about the preference for using a derma stamp over a derma roller for hair loss treatment, with users discussing its efficiency, needle material, replacement frequency, and personal experiences. Specific treatments mentioned include microneedling with a derma stamp.
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
PP405 and GT20029 are new hair loss treatments with different mechanisms from traditional options like Minoxidil and Finasteride. PP405 targets hair follicle stem cells to reactivate growth, while GT20029 works as an androgen receptor deleter, both requiring ongoing use for effectiveness.
The user shared their positive experience with a hair loss treatment regimen, which includes a diluted version of Hims finasteride spray, Kirkland 5% minoxidil, and weekly dermarolling. The user also mentioned taking hair multivitamins and plans to continue updating on their progress.
HMI-115, a potential treatment for hair loss that has been reported to produce significant regrowth in bald areas. It is the closest thing to a cure currently available and has raised hope that it could make hair transplants obsolete.
A user switched from a 1.5 mm derma roller to an adjustable dermastamp for microneedling to treat hair loss and found it less painful and more effective. Some users prefer different depths and tools like the Dr.Pen for microneedling, while others debate the necessity of depth and tool type.
New product Tomorrowlabs HSF targets hair loss through HIF pathway indirectly by removing scalp iron. Minoxidil and Stemoxydine also relate to HIF pathway.
A Phase 1 update for the HMI 115 clinical trial, which involves 16 participants and is expected to end in July 2023; as well as changes to the recruitment process, including treatment protocols with Minoxidil, Finasteride, and RU58841.
The post discusses hair loss treatments, specifically using large amounts of finasteride, minoxidil, and micro-needling. The comments suggest various other remedies, like monkey oil, rosemary oil, and biotin, while some advise to embrace baldness and focus on confidence.
There are no updates on GT20029, and concerns about its safety and effectiveness remain. The phase III trial has not started, and there are no new studies or data releases.
A 24-year-old with early hair loss is managing it with finasteride, minoxidil, and dutasteride, and is considering using a hair system for more styling options while maintaining transparency. They emphasize confidence and self-expression over hair, viewing it as an amplifier rather than a foundation.
A user's experience with using Fin for hair loss, which includes shedding and regrowth, potential side effects, and the use of supplements, protein, and exercise as additional treatments.
HMI 115 did not work as expected for hair regrowth in humans, unlike in macaque monkeys. There is anticipation for further research on prolactin's role in hair loss, with expectations that pharmaceutical companies will likely solve this before universities.
The conversation is about the anticipated release date of phase II results for a hair loss treatment called GT20029 and the cautious optimism surrounding it due to past disappointments with similar treatments. Users expect an update in the next few months.
The conversation discusses whether Harry Styles had a hair transplant, with opinions divided on whether he changed his hairstyle or underwent a procedure. It also touches on the use of medication and surgery as treatments for hair loss.
A European individual planning to go to China is seeking information on how to participate in HMI-115 trials for Androgenetic Alopecia. They've tried contacting Mrs. Yang and Mr. Wang for assistance but haven't received a response.
Haircafe is generally trusted for hair loss information, particularly for his evidence-based approach and recommendations of finasteride, dutasteride, and minoxidil. While some users appreciate his scientific focus and lack of product promotion, others criticize his dismissal of anecdotal evidence and certain biases.
The conversation is about using melatonin for hair loss, with users discussing different products and methods for topical application. They mention concerns about ingredients and cost, and one user suggests a magnesium scalp serum with melatonin.
The user shares their experience with a hair system, noting no one noticed the change except their girlfriend. They discuss the learning curve, maintenance tips, and their satisfaction with the results, feeling more confident and optimistic.
HairClone is offering a Dermal Papilla Cell Hair Multiplication procedure in Guatemala, raising questions about its effectiveness and regulatory reasons for the location. Users express skepticism and curiosity about the treatment's success and potential costs.